Gilead Sciences Chairman Daniel O'Day Sells 10,000 Shares Amid Overvaluation Concerns

Daniel O'Day, CEO of Gilead Sciences Inc (GILD), sold 10,000 shares on July 28, 2025, for $113.94 per share. This sale brings the total number of shares sold by O'Day to 30,000 over the past year. Gilead Sciences focuses on antiviral drugs and treatments for cardiovascular, respiratory, and oncology diseases. The company has a market cap of $142,094,021 million and a price-earnings ratio of 24.05.

Daniel Patrick O'Day, CEO of Gilead Sciences Inc (GILD), sold 10,000 shares of the company's stock on July 28, 2025, at an average price of $113.94 per share. This transaction, totaling $1,139,400, is part of a series of sales by O'Day over the past year, bringing his total shares sold to 30,000 [1].

Gilead Sciences, a biopharmaceutical company, specializes in antiviral drugs and treatments for cardiovascular, respiratory, and oncology diseases. The company's market capitalization stands at $142.09 billion, with a price-earnings ratio of 24.05 [1].

Following the sale, O'Day's ownership of Gilead shares decreased by 1.62%, with his total holding now valued at $69,016,306.50 [1]. The stock's performance has been positive, with shares rising 1.1% to $114.23 as of the latest trading day [1].

Institutional investors hold a significant portion of Gilead's stock, with 83.67% of the shares owned by institutional investors, reflecting strong confidence in the company's future performance [1]. Analysts have also shown optimism, with several firms upgrading their ratings and price targets for the stock [1].

The company's quarterly earnings report is expected on April 24, 2025, and analysts anticipate positive results, with a consensus price target of $126 [2]. The stock's technical indicators suggest a strong buy rating, with a 100% buy rating for both short and long-term horizons [2].

Despite O'Day's sales, Gilead Sciences continues to be a significant player in the biopharmaceutical industry, with a diverse portfolio of products and a strong market position. Investors should closely monitor the company's earnings report and analyst updates for further insights.

References:
[1] https://www.marketbeat.com/instant-alerts/insider-selling-gilead-sciences-inc-nasdaqgild-ceo-sells-10000-shares-of-stock-2025-07-29/
[2] https://stocksregister.com/2025/07/29/what-direction-does-gilead-sciences-inc-nasdaq-gild-analysts-think-the-company-will-take/